Five high conviction stocks in December
About the author:
- Author name:
- By Andrew Tang
- Job title:
- Analyst - Equity Strategy
- Date posted:
- 03 December 2018, 12:46 PM
- Sectors Covered:
- Equity Strategy and Quant
Volatility has returned with vigour over the past two months, with the ASX200 posting its third straight negative month in November. While we don't subscribe to the view that equity markets are heading into a deep bear market, macro events will determine market direction in coming weeks. With global growth moderating, investors could become more sensitive towards weaker economic data, exacerbating volatility.
The Year ahead
For major central banks, 2019 may be the year when the great monetary experiment, quantitative easing (QE), enters a new phase in which QE is gradually unwound. Equity markets have already had a good taste of how disruptive this process can be with three >5% corrections in the S&P/ASX 200 Index this year.
While stock valuations have reverted toward their long-run average we remind investors that volatility will remain a permanent fixture in the year ahead. The increased volatility in the market as a result of rising macro uncertainty and tighter financial conditions argues for a greater focus on portfolio resilience.
Five high conviction stocks in December
Our high conviction stocks are those that we think offer the highest risk-adjusted returns over a 12-month timeframe, supported by a higher-than-average level of confidence. They are typically our preferred sector exposures.
Here are our five high conviction ASX100 stock picks this month:
Cleanaway Waste Managment (CWY)
CWY is a provider of waste management services in Australia, with operations in both solid and liquid waste.
Key reasons to buy Cleanaway
- New management has worked to improve the cost base, capital intensity, revenue generation and balance sheet over recent years.
- Going forward we expect relatively defensive and solid earnings growth driven by organic sources, announced major contract wins and the acquisition of Toxfree (including cost-out synergies)
- With the growing importance of sustainability in household, business and government decision-making, we expect waste management to become an increasingly valuable sector where CWY is the Australian leader.
We retain our Add recommendation. Morgans clients can login to view our detailed research and share price target for Cleanaway Waste Management (CWY).
OZ Minerals (OZL)
OZ Minerals is a copper-focused international company based in South Australia.
Key reasons to buy OZ Minerals
- OZL enjoys robust cashflows from an established production base in copper, which has among the best outlooks in the commodities suite, driven by electrification of the developing world. OZL's balance sheet and cost structure provide good downside protection.
- We think OZL's counter-cyclical growth strategy will be rewarded as the Carrapateena development project is gradually de-risked in the coming 1-2 years, and can justify valuations closer to $12.50 per share upon successful commissioning.
- We think that recent share price weakness has been driven by macro-economic uncertainties, which we think can pass in time.
We retain our Add recommendation. Morgans clients can login to view our detailed research and share price target for OZ Minerals (OZL).
RMD is a global company involved in the development and manufacturing of medical products for the treatment and management of respiratory disorders, with a focus on sleep-disordered breathing. RMD sells a range of products in approximately 100 countries worldwide.
Key reasons to buy ResMed
- In our view the company remains well positioned with continued growth across masks and devices, a solid pipeline of new products and an expanding digital platform helping to drive resupply, low setup costs and improve adherence rates.
- 1Q results were above expectations, driven by the fifth straight quarter of double digit sales growth, an expanding product range, stable gross margins and strength in the company's leading connected-care offerings.
- RMD targets a very large potential market opportunity. The National Heart Blood and Lung Institute estimates that 12 million Americans suffer from sleep apnoea. According to RMD, fewer than 4 million are diagnosed or treated each year.
We retain our Add recommendation. Morgans clients can login to view our detailed research and share price target for ResMed (RMD).
Reliance Worldwide (RWC)
RWC is the world's largest manufacturer of push to connect (PTC) plumbing fittings and specialist water control valves.
Key reasons to buy Reliance Worldwide
- RWC hold the #1 market position in a number of product categories and is the clear market leader in the US with 80% market share (on a volume basis) in the residential PTC fittings category.
- It has a stable earnings growth profile focused on the less cyclical residential R&R sector with operations in North America, Asia-Pacific and Europe.
- PTC fittings penetration in the US is >10%. Given its strong value proposition we believe there is still a lot of potential for further penetration of the category over the long term.
We retain our Add recommendation. Morgans clients can login to view our detailed research and share price target for Reliance Worldwide (RWC).
Westpac Bank (WBC)
Westpac is Australia's oldest banking and financial services group, with operations throughout Australia and New Zealand.
Key reasons to buy Westpac
- WBC has a relatively low risk profile in terms of loan book positioning and low reliance on treasury and markets income.
- The bank stands to benefit most from re-pricing of investor home loans.
- We expect WBC to comfortably meet APRA's 'unquestionably strong' capital benchmark through undiscounted dividend reinvestment plans.
We retain our Add recommendation. Morgans clients can login to view our detailed research and share price target for Westpac Bank (WBC).
Morgans clients can access the detailed High Conviction Stocks research report which also includes an additional five ex-ASX100 companies. If you would like more information, please contact your adviser or nearest Morgans office.
Disclaimer: The information contained in this report is provided to you by Morgans Financial Limited as general advice only, and is made without consideration of an individual's relevant personal circumstances. Morgans Financial Limited ABN 49 010 669 726, its related bodies corporate, directors and officers, employees, authorised representatives and agents (“Morgans”) do not accept any liability for any loss or damage arising from or in connection with any action taken or not taken on the basis of information contained in this report, or for any errors or omissions contained within. It is recommended that any persons who wish to act upon this report consult with their Morgans investment adviser before doing so.
Disclosure of interest: Morgans may from time to time hold an interest in any security referred to in this report and may, as principal or agent, sell such interests. Morgans may previously have acted as manager or co-manager of a public offering of any such securities. Morgans affiliates may provide or have provided banking services or corporate finance to the companies referred to in the report. The knowledge of affiliates concerning such services may not be reflected in this report. Morgans advises that it may earn brokerage, commissions, fees or other benefits and advantages, direct or indirect, in connection with the making of a recommendation or a dealing by a client in these securities. Some or all of Morgans Authorised Representatives may be remunerated wholly or partly by way of commission.